Purpose: Comparison of mutation landscape across ethnics using the identical detecting platform is important. We explored the differential genomic landscape of patients with hormone-receptor positive (HR+), HER2-negative MBC of first line recurrence or Stage IV at diagnosis from the United States (US) and China (CN).Methods: Twenty-seven US patients and 65 CN patients had circulating tumor DNA (ctDNA) sequencing from plasma using the harmonized CLIA-certified, 152-gene PredicineCareTM liquid biopsy assay. Clinical outcomes were correlated with ctDNA variants. Progression-free survival (PFS) was performed for patients and compared using log-rank test. Results: All patients from CN cohort received chemotherapy and/or hormonal therapy, while 85.2% (23/27) patients of US cohort hormonal plus CDK4/6 inhibitor. Mutations were detected in 23 of 27 (85%) US patients and 54 of 65 (83%) CN patients. Prevalence of AKT1(18.5% vs. 3.1%, P = 0.008) and CDH1 were higher in US cohort (18.5% vs. 1.5%, P = 0.021), and gain of FGFR1 was higher in the CN cohort (7.4% vs. 24.6%, P = 0.048). PTEN deletion (5.7 months vs. 13.2 months, P = 0.03) and ESR1 alterations (9.0 months vs. 13.2 months, P = 0.02) were associated with significantly shorter PFS in CN cohort. However, the similar result was not found in US cohort. Conclusions: Differential prevalence of FGFR1, AKT1, and CDH1 in HR+ MBC were found between US and CN, which indicates a slight difference in a genomic setting. Meanwhile, certain genes such as PTEN and ESR1 shows varied predictive value across US and CN cohort regarding PFS.
Background: The differential mutation landscape between ethnics is more comparable when using the identical detecting platform.We explored the differences in genomic landscape of patients with hormone-receptor positive (HR+), HER2-negative MBC of first recurrence or Stage IV at diagnosis from the United States (US) and China (CN).Methods: Twenty-seven US patients and 65 CN patients had circulating tumor DNA (ctDNA) sequencing from plasma using the harmonized CLIA-certified, 152-gene PredicineCareTM liquid biopsy assay. Clinical outcomes were correlated with ctDNA variants. Progression-free survival (PFS) and overall survival analysis was performed for patients and compared using log-rank test. Results: Mutations were detected in 23 of 27 (85%) US patients and 54 of 65 (83%) CN patients. The most common mutations detected included TP53, PIK3CA, CDH1, AKT1, ESR1, and BRCA2 in both US and CN patients. AKT1(18.5% vs. 3.1%, P = 0.008) and CDH1 mutations were more frequent in the US population (18.5% vs. 1.5%, P = 0.021), and gain of FGFR1 was more common in the CN cohort (7.4% vs. 24.6%, P = 0.048). PTEN deletion (5.7 months vs. 13.2 months, P = 0.03) and ESR1 alterations (9.0 months vs. 13.2 months, P = 0.02) were associated with significantly shorter PFS in CN cohort. Conclusions: To our knowledge, this is the first real world study using a single harmonized ctDNA assay to profile plasma samples of patients from the US and CN. Differential prevalence of the mutations with therapeutic potential were found between US and CN.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.